We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insmed Stock Jumps 29% on Encouraging PAH Study Results
Read MoreHide Full Article
Key Takeaways
TPIP reduced pulmonary vascular resistance by 35% and improved the six-minute walk distance by 35.5 meters.
Insmed plans late-stage PAH trials in early 2026 after FDA talks on study design.
TPIP also showed promise in PH-ILD, with plans for late-stage trials starting in H2 2025.
Shares of Insmed (INSM - Free Report) soared nearly 29% yesterday after the company reported positive top-line data from a phase IIb study evaluating its investigational treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).
The study achieved its primary endpoint – TPIP-treated participants achieved a statistically significant reduction in pulmonary vascular resistance (PVR) levels. Specifically, treatment with the drug led to placebo-adjusted reductions of 35%. PVR measures pressure in the lung blood vessels.
The study also met all secondary efficacy endpoints. Treatment with the drug showed a placebo-adjusted improvement in a six-minute walk distance (6MWD) of 35.5 meters and a placebo-adjusted reduction of 60% in N-terminal pro b-type natriuretic peptide (NT-proBNP) concentrations. The 6MWD measures a patient’s exercise capacity, while NT-proBNP is a biomarker of heart strain.
Based on the above results, Insmed plans to “immediately engage” with the FDA on the design for a late-stage study on the drug in the PAH indication. It aims to start this study in early 2026. The company also plans to present detailed results from the study at a future medical meeting.
PAH is a rare, progressive disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood pressure in the pulmonary arteries and forcing the heart to work harder. Common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue and weakness. Insmed estimates that nearly 90,000 patients living across the United States, Europe and Japan are diagnosed with PAH.
INSM Stock Performance
Year to date, shares of Insmed have surged 32% against the industry’s 1% decline.
Image Source: Zacks Investment Research
More on INSM’s TPIP
Apart from PAH, Insmed is also developing TPIP for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Last year, the company reported results from a mid-stage study on the drug in PH-ILD patients. The data showed that treatment with TPIP has the potential to prolong the duration of the effect and reduce dose frequency compared with existing inhaled prostanoid therapies.
Based on these findings, Insmed intends to initiate a late-stage PH-ILD study in the second half of 2025, which may further expand TPIP’s competitive reach if successful.
Why Did UTHR Stock Decline on INSM’s News?
Insmed’s TPIP is a prodrug of United Therapeutics' (UTHR - Free Report) treprostinil, the active ingredient in its blockbuster Tyvaso products. A prodrug is an inactive compound that becomes active once inside the body, allowing TPIP to release treprostinil more gradually. This extended-release design enables once-daily dosing, compared to United Therapeutics’ Tyvaso, which requires multiple daily doses using either a nebulizer or a dry powder inhaler. Tyvaso products are approved for PAH and PH-ILD indications.
Across both the PAH & PH-ILD studies, Insmed claimed that a majority of patients who received TPIP reached the maximum dose of 640 micrograms (µg) following five weeks of treatment. This once-daily 640 µg dose of TPIP contains approximately 60% more treprostinil than current market products, which are dosed four times daily. If approved, TPIP’s simplified, once-daily, capsule-based inhalation could offer a meaningful advantage in convenience and adherence over Tyvaso’s more frequent dosing.
This potential threat to Tyvaso’s franchise likely contributed to the 14% decline in UTHR’s stock price yesterday. Shares of Liquidia Corporation (LQDA - Free Report) also declined 17% on the news, as Insmed’s promising data may create long-term headwinds for its newly approved Yutrepia, another inhaled treprostinil product that requires multiple daily doses.
Liquidia’s Yutrepia only recently entered the market after years of legal battles with United Therapeutics, which had sought to block its approval. UTHR sued both Liquidia and the FDA, but its broad exclusivity on dry-powder treprostinil expired last month, clearing the way for Yutrepia’s long-awaited FDA approval. While Tyvaso has been on the market since 2009 for PAH and was approved for PH-ILD in 2021, Yutrepia marked the first inhaled competitor for both indications.
Image: Bigstock
Insmed Stock Jumps 29% on Encouraging PAH Study Results
Key Takeaways
Shares of Insmed (INSM - Free Report) soared nearly 29% yesterday after the company reported positive top-line data from a phase IIb study evaluating its investigational treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).
The study achieved its primary endpoint – TPIP-treated participants achieved a statistically significant reduction in pulmonary vascular resistance (PVR) levels. Specifically, treatment with the drug led to placebo-adjusted reductions of 35%. PVR measures pressure in the lung blood vessels.
The study also met all secondary efficacy endpoints. Treatment with the drug showed a placebo-adjusted improvement in a six-minute walk distance (6MWD) of 35.5 meters and a placebo-adjusted reduction of 60% in N-terminal pro b-type natriuretic peptide (NT-proBNP) concentrations. The 6MWD measures a patient’s exercise capacity, while NT-proBNP is a biomarker of heart strain.
Based on the above results, Insmed plans to “immediately engage” with the FDA on the design for a late-stage study on the drug in the PAH indication. It aims to start this study in early 2026. The company also plans to present detailed results from the study at a future medical meeting.
PAH is a rare, progressive disease in which the blood vessels in the lungs narrow or become obstructed, leading to high blood pressure in the pulmonary arteries and forcing the heart to work harder. Common symptoms include shortness of breath, chest pain, dizziness or fainting, fatigue and weakness. Insmed estimates that nearly 90,000 patients living across the United States, Europe and Japan are diagnosed with PAH.
INSM Stock Performance
Year to date, shares of Insmed have surged 32% against the industry’s 1% decline.
Image Source: Zacks Investment Research
More on INSM’s TPIP
Apart from PAH, Insmed is also developing TPIP for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Last year, the company reported results from a mid-stage study on the drug in PH-ILD patients. The data showed that treatment with TPIP has the potential to prolong the duration of the effect and reduce dose frequency compared with existing inhaled prostanoid therapies.
Based on these findings, Insmed intends to initiate a late-stage PH-ILD study in the second half of 2025, which may further expand TPIP’s competitive reach if successful.
Why Did UTHR Stock Decline on INSM’s News?
Insmed’s TPIP is a prodrug of United Therapeutics' (UTHR - Free Report) treprostinil, the active ingredient in its blockbuster Tyvaso products. A prodrug is an inactive compound that becomes active once inside the body, allowing TPIP to release treprostinil more gradually. This extended-release design enables once-daily dosing, compared to United Therapeutics’ Tyvaso, which requires multiple daily doses using either a nebulizer or a dry powder inhaler. Tyvaso products are approved for PAH and PH-ILD indications.
Across both the PAH & PH-ILD studies, Insmed claimed that a majority of patients who received TPIP reached the maximum dose of 640 micrograms (µg) following five weeks of treatment. This once-daily 640 µg dose of TPIP contains approximately 60% more treprostinil than current market products, which are dosed four times daily. If approved, TPIP’s simplified, once-daily, capsule-based inhalation could offer a meaningful advantage in convenience and adherence over Tyvaso’s more frequent dosing.
This potential threat to Tyvaso’s franchise likely contributed to the 14% decline in UTHR’s stock price yesterday. Shares of Liquidia Corporation (LQDA - Free Report) also declined 17% on the news, as Insmed’s promising data may create long-term headwinds for its newly approved Yutrepia, another inhaled treprostinil product that requires multiple daily doses.
Liquidia’s Yutrepia only recently entered the market after years of legal battles with United Therapeutics, which had sought to block its approval. UTHR sued both Liquidia and the FDA, but its broad exclusivity on dry-powder treprostinil expired last month, clearing the way for Yutrepia’s long-awaited FDA approval. While Tyvaso has been on the market since 2009 for PAH and was approved for PH-ILD in 2021, Yutrepia marked the first inhaled competitor for both indications.
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.